Stocks Health care CRNX
NASDAQ · Health careCrinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. brought in $42.2M of revenue over the twelve months to June 30, 2026, up 2,928.4% from a year earlier. It posted a net loss of $501.6M. In fiscal 2025 capital spending exceeded operating cash flow by $383.7M. At June 30, 2026 it held $55.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What Crinetics Pharmaceuticals, Inc. does
Crinetics Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRNX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.7M | -$465.3M | -$4.95 | -$383.7M |
| 2024 | $1M | -$298.4M | -$3.69 | -$234M |
| 2023 | $4M | -$214.5M | -$3.69 | -$173.3M |
| 2022 | $4.7M | -$163.9M | -$3.15 | -$116.9M |
| 2021 | $1.1M | -$107.6M | -$2.80 | -$89M |
| 2020 | $71K | -$73.8M | -$2.42 | -$62.2M |
Where CRNX ranks in Health care
Latest SEC filings
What Crinetics Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Deregistration 15-12G
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
- September 1, 2026Form S-8 POS filing S-8 POS
Insider trades
What the people running Crinetics Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 33 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other change | 248,043 | $21.1M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 1,000 | $85K |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 136,805 | $11.6M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 106,000 | $9M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 110,000 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 100,000 | $8.5M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 111,100 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 111,100 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 111,100 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 111,100 | $9.4M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other changeindirect | 80,000 | $6.8M |
| September 1, 2026 | Struthers Richard ScottPresident & CEO, Director | Other change | 176,663 | $15M |
| September 1, 2026 | Schilke TobinChief Financial & Infra. Ofcr. | Other change | 7,956 | $676.3K |
| September 1, 2026 | Schilke TobinChief Financial & Infra. Ofcr. | Other change | 71,471 | $6.1M |
| September 1, 2026 | Betz Stephen F.Chief Scientific Officer | Other change | 58,286 | $5M |
Questions about CRNX
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRNX.
Is Crinetics Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $501.6M on revenue of $42.2M.
How much revenue does Crinetics Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Crinetics Pharmaceuticals, Inc. reported revenue of $42.2M. That is 2,928.4% more than a year earlier.
When did Crinetics Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the deregistration from September 11, 2026.
Similar companies
Compare CRNX with
Follow CRNX
Get an email when Crinetics Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CRNX: get an email when it filesWhere the numbers come from
Financial figures are the values Crinetics Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.